Repealing California's single sales factor tax apportionment not only will revive a failed tax regulation that imposed penalties on biotech companies for creating jobs and economic growth in the state but also will stifle the development of promising treatments, BayBio President and CEO Matthew M. Gardner writes in this commentary piece. The adoption of the sales tax reform will help the state weather the recession and pay for key services, Gardner writes.

Related Summaries